Abstract 933P
Background
Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine malignancy with a higher case-fatality rate than melanoma. The prognosis of MCC is complex and depends on many factors. In this study, we aimed to develop predictive survival models using machine learning (ML) algorithms and statistical techniques for patients with head and neck MCC.
Methods
Using a cohort of 1,372 patients diagnosed with MCC of the head and neck region in the United States between 2000 to 2019 sourced from the Surveillance, Epidemiology, and End Results (SEER) Program, we developed and evaluated a cox-proportional hazards (CPH) regression model, nine classification and regression ML models, and two ML-based survival models. Models were built with a total of 20 features, including demographic, cancer-related and treatment/surgery-related variables. Pre-processing, hyperparameter tuning, classification, regression, survival analyses, and model evaluations were performed using ‘scikit-learn', ‘scikit-survival', and ‘lifelines' packages on Python 3.80.
Results
The mean age of patients was (66.0). Most cases were diagnosed in stage I (n=723, 52.7%). Multivariate CPH model yielded a Concordance-Index (C-Index) = 0.700 on the test set, outperforming both random forest survival (C-Index = 0.591) and survival tree (C-Index = 0.582) algorithms. Of the nine classification models, gradient boosting classifier predicted the most accurate 2-year (AUC = 0.75; accuracy= 0.71) and 5-year (AUC = 0.75; accuracy = 0.68) survival. Additionally, the ridge- and lasso-regularized linear models performed the most accurate regression (RMSE = 1182.84, R2 = 0.2259; RMSE = 1184.70, R2 = 0.2234, respectively), and the gradient boosting regressor had acceptable predictions (RMSE = 1189.64, R2 = 0.2170) on test sets. According to the Shapley Additive Explanations (SHAP) value analysis, the most critical feature of these regression models was age, followed by sex and AJCC stage.
Conclusions
This study found that machine learning and statistical models provide reliable survival predictions for head and neck Merkel cell carcinoma, with models like gradient boosting classifiers having acceptable outputs, especially for 2-year survival.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
938TiP - Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Amanda Psyrri
Session: Poster session 03
941TiP - A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Saira Khalique
Session: Poster session 03
942TiP - A randomized controlled clinical trial of neoadjuvant immunochemotherapy vs up-front surgery in patients with locally advanced resectable oral squamous cell carcinoma (Tophill trial)
Presenter: Laiping Zhong
Session: Poster session 03
Resources:
Abstract
945TiP - JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Presenter: Jean-Pascal Machiels
Session: Poster session 03
1002P - A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safety
Presenter: Ruofan Huang
Session: Poster session 03
1003P - A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
Presenter: Mathilde Beaufils
Session: Poster session 03